Low Frequency TMS for Depression in Epilepsy
(LFTMS Trial)
Recruiting in Palo Alto (17 mi)
Overseen byKrzysztof A. Bujarski, MD
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Dartmouth-Hitchcock Medical Center
No Placebo Group
Approved in 3 Jurisdictions
Trial Summary
What is the purpose of this trial?
The purpose of this study is to determine if low-frequency transcranial magnetic stimulation (TMS) is safe and feasible for treating depressive symptoms in patients with epilepsy. Patients will receive an accelerated protocol of TMS consisting of three consecutive days of treatment. Patients will have in-person follow up visits after one month and again after six months.
Eligibility Criteria
Inclusion Criteria
Age 18 or older
Able and willing to provide informed consent.
Diagnosis of epilepsy confirmed by the study neurologist (KB).
See 5 more
Treatment Details
Interventions
- Transcranial Magnetic Stimulation (Transcranial Magnetic Stimulation)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Low Frequency TMS InterventionExperimental Treatment1 Intervention
Patients will receive low-frequency TMS on an accelerated schedule over three consecutive days.
Transcranial Magnetic Stimulation is already approved in United States, Canada, European Union for the following indications:
🇺🇸 Approved in United States as Transcranial Magnetic Stimulation for:
- Major Depressive Disorder
- Obsessive Compulsive Disorder
🇨🇦 Approved in Canada as Transcranial Magnetic Stimulation for:
- Major Depressive Disorder
🇪🇺 Approved in European Union as Transcranial Magnetic Stimulation for:
- Major Depressive Disorder
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Dartmouth Hitchcock Medical CenterLebanon, NH
Loading ...
Who Is Running the Clinical Trial?
Dartmouth-Hitchcock Medical CenterLead Sponsor
The Diamond Foundation Inc.Collaborator
The Diamond FoundationCollaborator